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1760+]Helicobe*rWlori~~dcVo~*g~,ovi~u~,~fe~*i*n~
ereStronglyAssociatedwithAtherosclerosis,but
arenotResponsiblefortheInstabilityofAngina
G. Liuzzo, G. Caligiuri, R.L. Grille, A. Buffon, C. Monaco, V. Pasceri,
D.J. Angiolillo, F.Crea, L.M. Biaaucci, A. Maserl. Cartf/o/og~ Catfro/ic
Urriversify Rome, /ta/y
Several studies suggest an association between bacterial and viral infections
and the risk of ischemic heart disease. To investigate whether these infec-
tions have also a pathogenetlo role In unstable angina (UA) serum levels
of antibodies to Helioobacrer pyloti (HP) and Cytomegalovirus (CMV) were
meaeured in 38 pts with class IIIB UA, in 22 pte with chronic stable angina
(CSA) lasting >1 yr, in 32 pts with diffuse peripheral vascular diseese (PVD)
as assessed by arteriography before vascular surgety, and in 42 healthy
subjects (N). The severity of angiographically assessad mronary atheroscle-
rosis was similar in UA and CSA. Subjecte were considered as seropoaitive
when serum levels of speoific lgG to HP and CMV were >10 U/ml and >6
U/ml, respectively.
Numberofsubjectssaropositiveto:
N~lthW HP Ghfv Both
UA 2 (6”A)* 29 (76”A)* 36 (!32%)” 28 (74%)*
GSA 1 (5%)* 19 (86%)*t 20 (91%)* 18 (82%)*
PVD 2 (6%)* 18 (56%) 30 (94%)* 1s (56%)”
N 16 (36%) 15 (36%) 21 (50%) 10 (24%)
‘P <0.01 vs N.tP <0.05 VS PVD
The prevalence and the titre of HP and CMV antibodies was similar in pts
with UA and CSA, and in pts with PVD. No association was found between
the presence and the titre of HP and CMV antibodies and prognosis In
UA. Tharefore, HP and CMV infections, although strongly associated with
atherosclerosis, are unlikely to play a major role in the instability of angina.
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17’60-41ARando~l~adTri~lforTreat~ent~funstable
Anginain PatientswithRestenosisPostCoronary
Anglopleety
M. Malekianpour, S. Doucet, P.Th6roux, G. CM6, L. Bilodeau, J.-C. Tardif,
P.deGuise. Montreal Heart Institute, Montreal, (Quebao), Canada
Unstable angina (UA) is a heterogeneous syndrome and when related to
restenosis appears to be eeeociatad with a low risk of serious complications
due to a probable difference in ita underlying mechanism with increased
vasoreastlvity. We presant the results of a randomized doubla-blind study,
designed to determine the effioeoy of intravenous nitroglycerin (NTG) and
hepann (HEP) in treatment of patients presenting with UA within 6 months of
a successful coronary angioplaaty. UA was defined as recurrent exertional
or rest chest pain of >5 min duration within 24 hours of admisaion. 200
patients were randomized to one of 4 treatment groups; 1) NTG, 2) HEP,
3) NTG plua HEP and 4) placebo, for an average of 62 + 30 hours. Oral
antianginal medication and aspirin were continued. Analysis for the first 185
patients demonstrated angiographic restenosis (?50%) in 154 (63%). There
was no myocardial infarction or death in these patients but recurrant angina
with or without ECG changea waa present in 57% of the patients. NTG was
significantly better in preventing recurrent angina and avoiding the need for
an urgent angicgram due to refractory angina. HEP had similar effect to
placetw end offered no advantage in combination with NTG.
NTG(n46) HEP(n47) NTG+ HEP(n49) Placebo(n43)
Noangina 58.7 29.8 55.1 27,9
Recurrentangina 41.3* 70.2 44.9t 72.1
Refrsctotyanginaw 4.3** 27.7 8.2* 20.9
Veluasas% forcolumna,‘Protocol atoopadlurgentangiogram,*P <0.003 vs placebo
(RR0.57),**p= 0.002vsplacebo(RR1.6),tp < 0.008vsplacsbo(RR0.62),ttp=0.01
vsplacebo(RR1.5)
Conclusions: In UA sssondaty to restenosis; 1) IV NTG offers the best
choice for relief of eymptoms 2) HEP offers no additional benefit 3) risk of
serious oomplioations is low 4) these results suggest a different undettying
pathophyeiologicel meohanism.
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implementationofAHCPRGuidelinesfor Unstable
Anginain 1996:UnfortunateDifferencesbetw~n
Men& WomenResultsfromthe Multicenter
GUARANTEERegistry
C.P.Cannon, D.J. Moliterno, N. Every, H.V. Andereon, F,V,Aguirre,
C.B. Granger, C.T. Lambrew, L.E. Rabbani, A. Arnold, B.M. Scirica,
S. Sapp, J.E. Booth, J.J. Ferguson, for the GUARANTEE Irtvestlgatore,
Brigham and Women3 Hospital, Boston, MA, USA
In order to Improve the care of patients with unstable angina, the Agency
for Health Care Policy Research sponaored a panel to develop a clinical
practice guideline. It recommended medical, diagnostic and intetventional
approaches to patients with unstable angina. However, no data are available
on its implementation in current practice. Accordingly, we evaluated 2,619
consecutive pts with unstable angina admitted to 35 hospitals across the US
in 1996, comparing men and women:
Men Women Pvalua
NumlMrofPte 1732 1104 -
A$pirin onadmission ,946, 79% WQ4
Heparinonadmi$gion 65% 59% 0.001
Sata-blackersonadmlsslon 537s 49% 0.032
Appropriatecathreferral 58% 54% O.oot
ApproprlsteCABGreferrel 46% 387. 0.142
Aspkin,heparin,andbeta-blockersonadmiaaion
andaspirinorcoumacfinatDIG 31% 24”h 0,001
Conclusions: 1) Despite the 1994 AHCPR Guidelines, significant propor-
tions of patients in 1996 did not receive the recommended therspias. 2)
Theae preliminary data suggest that women receive leas aggressive medical
treatment and diagnostic eveiuation. 3) Our findings suggest that the AHCPR
guidelines need to be implemented more aggressively, especially in women.
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~760-61 ReductionofmYo~ardialdamag*bYprolonged
treatmentwithS.C.lowmolecularweightheparin
(LMWH)inunstableCAD
H. Saetre, B. Lindahl, L. Wallentin, for the FRISC study group, Dept of
Cardiolog~ Llnivereifyof Uppssla, Sweden
The Selvester QRS-scoring system in 12 lead Ecg ie an indicator of eize of
acute myocardial infarction (Ml). in the FRISC atudy patients with unetable
coronary artaty disease, i.e. unstable angina or non-Q-wave myocardial in-
farction, were randomized to LMWH or placebo. In order to evaluate whether
LMWH reduced not only clinically diagnosed reinfarction but also the final
development of myocardial damage (QRS-scores)were evaluated in 85% of
the original patients.
Dasign: The 1276 patients, aged 40-90 (median 70) yeara, 36% women,
were admitted because of chest pain and ST-depr. or T-wave inv. and ran-
domized to S.C.LMWH (dalteparin) 120 U/kg b.w. (msx 10.000 U) every 12 h
for6d (6am. and 6 p.m.) followed by7500U every24 h (6 p.m.) for40 d. Ret-
rospective inclusion diagnoeia based on elevation of cardrac enzymee waa
non-Q-wave Ml in 37% and unstable angina in 63%. QRS-ecoring with tha
32 point Selveeter system was performed in ECG-recordinge at admission,
at discharge after 5-6 days and at the follow-up visit affar 4045 days.
Reeultsat 6 daysand40days:
Placebo Dalteparin RR(conf,Intmval)
At6 days
ReductionQRS-acorez 2 p 11.4
ReductionQRS-scorez 3 p 5.5
ClinicalnewMl% 3,7
NewMlor Red.QRSz 3p S.o
At40 days
ReductionQRS-acorez 2 p ~RS 14,5
RaductlonQRS-ecorez 3 p 6,3
ClinicalnewMl% 8.2
NewMlor Red.QRSz 3 p 13.6
8.0
3,7
0.9
4.5
10.3
5.3
5.7
9.9
0,70 (0.50-0.ss)
0.66 (0,40-1.11)
0.25 (0.10-0.62)
0.56 (0.354,87)
0.71(OS&3.96)
0.S4(0.42-0.98)
0.69(0.4e-1,04)
0.73(0s4-0.99)
Conclusion: After 6 daya high dose LMWH the occurrence of reinfarotion
is reduced more than myccardial damage because of the preaence of non-
Q-wava Ml before treatmant in 37% of pts. After another 5 weeke with low
dose LMWH there ia a remaining comparable reduction in both myocardial
damage and clinical reinfarction.
